Chemotherapy Naive Prostate Cancer
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB08899 | Enzalutamide | A second-generation androgen receptor inhibitor used to treat castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB08899 | Enzalutamide | Serum albumin | carrier |
| DB08899 | Enzalutamide | Cytochrome P450 2C8 | enzyme |
| DB08899 | Enzalutamide | Cytochrome P450 3A4 | enzyme |
| DB08899 | Enzalutamide | Androgen receptor | target |
| DB08899 | Enzalutamide | Cytochrome P450 2C9 | enzyme |
| DB08899 | Enzalutamide | Cytochrome P450 2C19 | enzyme |
| DB08899 | Enzalutamide | Cytochrome P450 2B6 | enzyme |
| DB08899 | Enzalutamide | Cytochrome P450 3A5 | enzyme |
| DB08899 | Enzalutamide | P-glycoprotein 1 | transporter |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB01590 | Everolimus | 2 | Terminated | 1 |
| DB06663 | Pasireotide | 2 | Terminated | 1 |